彭布罗利珠单抗
医学
封锁
免疫疗法
生物标志物
癌症
肿瘤科
免疫检查点
癌症免疫疗法
内科学
受体
遗传学
生物
作者
Xinan Wang,Giuseppe Lamberti,Alessandro Di Federico,Joao V. Alessi,Roberto Ferrara,M.L. Sholl,Mark M. Awad,Natalie I. Vokes,Biagio Ricciuti
标识
DOI:10.1016/j.annonc.2024.03.007
摘要
Tumor mutational burden (TMB) is a biomarker that measures the number of somatic mutations in a tumor's genome. TMB has emerged as a predictor of response to immune checkpoint inhibitors (ICIs) in various cancer types, and several studies have shown that patients with high TMB have better outcomes when treated with PD-(L)1-based therapies. Recently, the FDA has approved TMB as a companion diagnostic for the use of pembrolizumab in solid tumors. However, despite its potential, the use of TMB as a biomarker for immunotherapy efficacy is limited by several factors. Here we review the limitations of TMB in predicting immunotherapy outcomes in patients with cancer and discuss potential strategies to optimize its use in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI